Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
AssigneesDeutsches Krebsforschungszentrum, Ruprecht-Karls-UniversitäT Heidelberg
InventorsBarbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
Life of this patent
Estimating the term…
Abstract
The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
Claims6
A pharmaceutical combination containing (a) parvovirus H-1 and (b) an anti-PD1 antibody or an anti-PD-L1 antibody.
A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing parvovirus H-1, the second container comprises at least one dose of a pharmaceutical composition comprising an anti-PD1 antibody or an anti-PD-L1 antibody, and the package insert comprises instructions for treating an individual having cancer using the pharmaceutical composition(s).
Dependencies are inferred from the claim text.